Filtered By:
Condition: Heart Failure
Countries: Canada Health
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 181 results found since Jan 2013.
Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registry
ConclusionA sizeable proportion of patients with chronic coronary syndrome develop HF, which only infrequently requires hospitalization. Early identification of patients with HF may lead to early treatment, and help to further decrease mortality and morbidity. This concept needs confirmation in future studies.
Source: European Journal of Heart Failure - April 14, 2020 Category: Cardiology Authors: Zofia Parma,
Adam Jasilek,
Nicola Greenlaw,
Roberto Ferrari,
Ian Ford,
Kim Fox,
Jean ‐Claude Tardif,
Michal Tendera,
P. Gabriel Steg Tags: Research Article Source Type: research
Good news and bad news: Changing trends in cardiovascular disease in Canada
(Elsevier) An analysis of patient records in Canada provides important new insights into changing patterns of inpatient healthcare utilization. Between 2007 and 2016, standardized hospitalization rates declined for coronary artery and vascular disease, heart rhythm disorders, stroke, and heart failure but increased for some important conditions: acquired valvular heart disease; vascular cognitive impairment; and congenital heart disease. The study appears in the Canadian Journal of Cardiology, published by Elsevier.
Source: EurekAlert! - Medicine and Health - July 2, 2020 Category: International Medicine & Public Health Source Type: news
Patterns Changing for Heart Disorder Hospitalizations in Canada
FRIDAY, July 10, 2020 -- Standardized hospitalization rates declined for coronary artery and vascular disease, heart rhythm disorders, stroke, and heart failure in Canada from 2007 through 2016, according to a study published online July 1 in the...
Source: Drugs.com - Pharma News - July 10, 2020 Category: Pharmaceuticals Source Type: news
Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association.
c Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research
Abstract
Cannabis, or marijuana, has potential therapeutic and medicinal properties related to multiple compounds, particularly Δ-9-tetrahydrocannabinol and cannabidiol. Over the past 25 years, attitudes toward cannabis have evolved rapidly, with expanding legalization of medical and recreational use at the state level in the United States and recreational use nationally in Canada and Uruguay. As a res...
Source: Circulation - August 4, 2020 Category: Cardiology Authors: Page RL, Allen LA, Kloner RA, Carriker CR, Martel C, Morris AA, Piano MR, Rana JS, Saucedo JF, American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Bas Tags: Circulation Source Type: research
Antiarrhythmic and cardiac electrophysiological effects of SZV-270, a novel compound with combined Class I/B and Class III effects, in rabbits and dogs.
In conclusion, SZV-270 with its combined Class I/B and III effects can prevent re-entry arrhythmias with reduced risk of provoking drug-induced Torsades de Pointes.
PMID: 32970956 [PubMed - as supplied by publisher]
Source: Canadian Journal of Physiology and Pharmacology - September 23, 2020 Category: Drugs & Pharmacology Authors: Varga RS, Hornyik T, Husti Z, Kohajda Z, Krajsovszky G, Nagy N, Jost N, Virág L, Tálosi L, Mátyus P, Varró A, Baczkó I Tags: Can J Physiol Pharmacol Source Type: research
The Impact of Sex and Gender on Heart-Brain Axis Dysfunction: Current Concepts and Novel Perspectives.
Abstract
The Heart-Brain Axis (HBA) recapitulates all the circuits that regulate bidirectional flow of communication between heart and brain. Several mechanisms may underlie the interdependent relationship involving heterogeneous tissues at rest and during specific target organ injury, such as myocardial infarction, heart failure, arrhythmia, stroke, mood disorders or dementia. In-depth translational studies of the HBA dysfunction under single-organ injury should include both male and female animals to develop sex/gender-oriented prevention, diagnosis and treatment strategies. Indeed, sex and gender are determinin...
Source: Canadian Journal of Physiology and Pharmacology - September 30, 2020 Category: Drugs & Pharmacology Authors: Baroni C, Lionetti V Tags: Can J Physiol Pharmacol Source Type: research
Left ventricular concentric remodeling and impaired cardiorespiratory fitness in patients with heart failure and preserved ejection fraction.
CONCLUSIONS: Post-exercise reduced LV volumes correlate with measures of impaired CRF in patients with HFpEF, thus supporting a pathophysiologic role of concentric remodeling in impaired CRF in HFpEF.
PMID: 32996304 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - October 2, 2020 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
Regulatory Role of Cardiomyocyte Metabolism via AMPK Activation in Modulating Atrial Structural, Contractile, and Electrical Properties Following Atrial Fibrillation.
Abstract
Patients diagnosed with atrial fibrillation (AF) have been rising due to increased incidence, enhanced detection methods, and greater survival rates following diagnosis. Due to this increase, AF is now the most commonly diagnosed arrhythmia in clinical practice. AF is characterized by irregular, high-frequency contractions of atrial myocytes that lead to turbulent blood flow and the potential for thrombus formation, stroke, or heart failure. These high-frequency contractions of the atrial myocytes cause an imbalance between metabolic supply and demand. Although advances have been made in understanding the...
Source: Canadian Journal of Physiology and Pharmacology - October 13, 2020 Category: Drugs & Pharmacology Authors: Brown SM, Larsen NK, Thankam FG, Agrawal DK Tags: Can J Physiol Pharmacol Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial
Introduction
Sleep-time blood pressure correlates more strongly with adverse cardiovascular events than does daytime blood pressure. The BedMed trial evaluates whether bedtime antihypertensive administration, as compared with conventional morning use, reduces major adverse cardiovascular events.
Methods and analysis
Design
Prospective randomised, open-label, blinded end-point trial.
Participants
Hypertensive primary care patients using blood pressure lowering medication and free from glaucoma.
Setting
Community primary care providers in 5 Canadian provinces (British Columbia, Alberta, Saskatchewan, Manitoba and Ontario) a...
Source: BMJ Open - February 24, 2022 Category: General Medicine Authors: Garrison, S. R., Kolber, M. R., Allan, G. M., Bakal, J., Green, L., Singer, A., Trueman, D. R., McAlister, F. A., Padwal, R. S., Hill, M. D., Manns, B., McGrail, K., O'Neill, B., Greiver, M., Froentjes, L. S., Manca, D. P., Mangin, D., Wong, S. T., MacLea Tags: Open access, Cardiovascular medicine Source Type: research
Cardiodiabetology: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks
Can J Physiol Pharmacol. 2022 Jun 30. doi: 10.1139/cjpp-2022-0065. Online ahead of print.ABSTRACTGlobally, nearly 500 million adults currently have diabetes, which is expected to increase to approximately 700 million by 2040. Cardiovascular diseases (CVD), including coronary heart disease, stroke, heart failure, and peripheral arterial disease, are the principal causes of death in persons with diabetes. Key to the prevention of CVD is optimization of associated risk factors. However, few persons with diabetes are at recommended targets for key CVD risk factors including LDL-cholesterol, blood pressure, HbA1c, nonsmoking st...
Source: Canadian Journal of Physiology and Pharmacology - June 30, 2022 Category: Drugs & Pharmacology Authors: Nathan D Wong Source Type: research
